Biotechnology company developing antibodies that selectively target TNF and other TNF superfamily members
Biotechnology company developing antibodies that selectively target TNF and other TNF superfamily members. Its approach aims to improve the benefit-risk profile of TNF-targeting treatments for inflammatory and autoimmune diseases and enable new bispecific therapies.